www.pfizerclinicaltrials.com Open in urlscan Pro
2606:4700:4400::6812:2186  Public Scan

Form analysis
2 forms found in the DOM

GET /find-a-trial

<form class="search-form" id="views_exposed_form" method="get" action="/find-a-trial">
  <div class="top-form">
    <div class="form-item-group">
      <div class="form-item">
        <div class="title-item"><span>Search</span>
          <div class="tooltip"><i class="icon-info"></i></div>
        </div>
        <div class="input"><input id="edit-search--2" type="text" name="search" size="60" placeholder="By condition, keyword or NCT#" class="condition-search-input form-text form-control flexdatalist flexdatalist-set"
            data-once="pfeAdobeAnalyticsSearchForm" style="position: absolute; top: -14000px; left: -14000px;"><input type="text" class="condition-search-input form-text form-control flexdatalist-alias edit-search--2-flexdatalist"
            placeholder="By condition, keyword or NCT#" name="flexdatalist-search" id="edit-search--2-flexdatalist" value="" autocomplete="off" data-once="pfeAdobeAnalyticsSearchForm"></div>
        <ul class="autocomplete"></ul>
      </div>
    </div>
  </div>
  <div class="bottom-form js-bottom-form hide">
    <h4>Filter by</h4>
    <div class="form-item-group">
      <div class="form-item location">
        <div class="title-item"><span>Location</span></div>
        <div class="input"><input id="edit-location--2" type="text" name="location" size="60" placeholder="City, State or ZIP Code" class="location form-autocomplete ui-autocomplete-input"
            data-autocomplete-path="/autocomplete/clinical_trial/location.json" data-drupal-selector="edit-location" data-once="autocomplete pfeAdobeAnalyticsSearchForm" autocomplete="off"><i class="icon-location"></i></div>
        <ul class="autocomplete"></ul>
      </div>
      <div class="form-item age">
        <div class="title-item"><span>Age (years)</span>
          <div class="tooltip"><i class="icon-info"></i></div>
        </div>
        <div class="input"><input id="edit-age--2" type="text" name="age" size="60" placeholder="Enter age" class="fat-age-input" data-once="pfeAdobeAnalyticsSearchForm"></div>
      </div>
      <div class="form-item">
        <div class="title-item"><span>Sex</span>
          <div class="tooltip"><i class="icon-info"></i></div>
        </div>
        <div class="radio-group"><input id="male-form-pr6Y_synIGAQA6-QhkoJb_-EawiojzbiE_6H3ki3gk8" type="radio" name="gender" value="1" data-once="pfeAdobeAnalyticsSearchForm"><label for="male-form-pr6Y_synIGAQA6-QhkoJb_-EawiojzbiE_6H3ki3gk8"
            class="radio"> Male</label><input id="female-form-pr6Y_synIGAQA6-QhkoJb_-EawiojzbiE_6H3ki3gk8" type="radio" name="gender" value="2" data-once="pfeAdobeAnalyticsSearchForm"><label
            for="female-form-pr6Y_synIGAQA6-QhkoJb_-EawiojzbiE_6H3ki3gk8" class="radio"> Female</label></div>
      </div>
    </div>
  </div>
  <h3 class="show-filter js-show-filter" data-once="pfeAdobeAnalyticsSearchForm">Show filters <i class="icon-arrow-down arrow"></i></h3>
  <div class="btn-wrapper">
    <div class="loading-element" style="display: none;"><span class="loaderdot"></span><span class="loaderdot"></span><span class="loaderdot"></span></div><button class="btn" data-once="pfeAdobeAnalyticsSearchForm">Find a trial
      <i class="icon-arrow-right"></i></button>
  </div>
  <div class="hidden-input">
    <div class="input"><input id="current_language" type="hidden" name="current_language" value="en" data-once="pfeAdobeAnalyticsSearchForm"></div>
  </div><input type="hidden" id="distance" name="distance" value="1000" data-once="pfeAdobeAnalyticsSearchForm">
  <div class="btn-wrapper filter-btn-wrapper">
    <div class="loading-element" style="display: none;"><span class="loaderdot"></span><span class="loaderdot"></span><span class="loaderdot"></span></div><button class="btn" data-once="pfeAdobeAnalyticsSearchForm">Find a trial
      <i class="icon-arrow-right"></i></button>
  </div>
</form>

POST /HCP/Be6A/C575

<form class="node-basic-page-4587-updown-was-this-helpful-0 vote-form rating-entity-4587-4587" id="rate-widget-base-form" data-drupal-selector="node-basic-page-4587-updown-was-this-helpful-0" action="/HCP/Be6A/C575" method="post"
  accept-charset="UTF-8">
  <table class="rating-table">
    <tbody>
      <tr class="rating-table-tr">
        <td class="rating-table-td">Is this page helpful?</td>
        <td class="rating-table-td">
          <div class="thumbsupdown-rating-wrapper rate-enabled" can-edit="true">
            <div class="rating form-item js-form-item form-type-radio js-form-type-radio form-item-value js-form-item-value"><label
                class="rating form-item js-form-item form-type-radio js-form-type-radio form-item-value js-form-item-value rating-label thumbsupdown-rating-label thumbsupdown-rating-label-up"><input twig-suggestion="rating-input"
                  class="rating-input thumbsupdown-rating-input form-radio" data-drupal-selector="edit-value-1" type="radio" id="edit-value-1" name="value" value="1" data-rating-selector="rating-entity-4587-4587"></label></div>
            <div class="rating form-item js-form-item form-type-radio js-form-type-radio form-item-value js-form-item-value"><label
                class="rating form-item js-form-item form-type-radio js-form-type-radio form-item-value js-form-item-value rating-label thumbsupdown-rating-label thumbsupdown-rating-label-down"><input twig-suggestion="rating-input"
                  class="rating-input thumbsupdown-rating-input form-radio" data-drupal-selector="edit-value-1-2" type="radio" id="edit-value-1--2" name="value" value="-1" data-rating-selector="rating-entity-4587-4587"></label></div>
          </div><input autocomplete="off" data-drupal-selector="form-yjgtc6skfga0eanuv4nwlrd4-77exqby-leddjw7gy" type="hidden" name="form_build_id" value="form-_yjgtc6sKfGa0EAnUv4nWLrd4_77exQbY_leDDJW7gY"><input
            data-drupal-selector="edit-node-basic-page-4587-updown-was-this-helpful-0" type="hidden" name="form_id" value="node_basic_page_4587_updown_was_this_helpful_0">
        </td>
      </tr>
    </tbody>
  </table>
</form>

Text Content

Skip to main content
Menu
 *   OVERVIEW
   * * About clinical trials
     * How clinical trials work
     * Protecting your safety & privacy
     * Steps to join a clinical trial
     * Diversity and inclusion
     PARTICIPANTS & CAREGIVERS
   * * For current clinical participants
     * For past clinical participants
     * Information for caregivers
 *   AREAS OF RESEARCH
   * * Our research
     * Inflammation & Immunology
     * Internal Medicine
     * Oncology
     * Pediatric
     * Rare Diseases
     * Vaccines
 *   OUR RESEARCH UNIT
   * * Pfizer Clinical Research Unit (PCRU)
     * PCRU trial list
     * Referral program
     * Participant loyalty program
     RESOURCES
   * * Hear from clinical participants
     * Educational tools & resources
     * FAQs

 * JOIN PFIZERLINK — A CLINICAL RESEARCH REGISTRY
   
   Get notified about Pfizer clinical trials that may be right for you — now and
   over time.
   
   Visit PfizerLink

Home

 * English

Find a trial


REFINE YOUR SEARCH


FIND A PFIZER CLINICAL TRIAL

Search



FILTER BY

Location

Age (years)


Sex

Male Female


SHOW FILTERS


Find a trial


Find a trial


SIGVOTATUG VEDOTIN (SV/SGN-B6A):


A NOVEL INTEGRIN
BETA-6-DIRECTED THERAPEUTIC APPROACH IN CANCER

The information provided on this page is intended for health care professionals
in the United States only.

Get Started



SIGVOTATUG VEDOTIN (SV/SGN-B6A):


A NOVEL INTEGRIN
BETA-6-DIRECTED THERAPEUTIC APPROACH IN CANCER

The information provided on this page is intended for health care professionals
in the United States only.

Get Started




The Be6A program is a series of clinical studies evaluating sigvotatug vedotin
in multiple solid tumors expression integrin beta-6 (IB6)

Sigvotatug vedotin is a first-in-class investigational antibody-drug conjugate
(ADC) designed to deliver the cytotoxic payload monomethyl auristatin E (MMAUE)
to cells expressing IB6. IB6 is a surface cell receptor overexpressed in many
solid tumors, such as non-small cell lung cancer (NSCLC), head and neck squamous
cell carcinoma (HNSCC), esophageal cancer, and cutaneous squamous cell
carcinoma.1

Data from the initial clinical study of sigvotatug vedotin demonstrates
preliminary and encouraging antitumor activity and durability with a tolerable
and manageable safety profile in heavily pretreated patients.2,3

Read on to learn more about sigvotatug vedotin and cancers that overexpress IB6
to see if your patients may qualify for enrolling studies.


PROPOSED MECHANISM OF ACTION

Sigvotatug Vedotin is thought to induce tumor cell death through:

 * Direct cytotoxicity via preferential release of MMAE within target cells and
   subsequent apoptosis
 * The bystander effect
 * Immunogenic cell death4,5




ABOUT IB6-OVEREXPRESSING CANCERS

IB6 is a member of the integrin family of proteins involved in cellular
adhesion, motility, and cytokinesis. IB6 is expressed at low levels in normal
adult epithelial tissues, but expression is induced by tissue injury due to its
role in wound repair.6 High levels of IB6 expression have been demonstrated in
different types of cancer1 and are associated with poor prognosis based on
multiple retrospective analyses.7,8 Additional investigations suggest tumors may
exploit the remodeling function associated with IB6 to promote invasiveness and
metastasis.9,10

Recruiting
Sigvotatug Vedotin for Non-Small Cell Lung Cancer (Be6A-LUNG-01)

This Phase 3 study will evaluate sigvotatug vedotin versus docetaxel for
patients with previously treated metastatic non-small cell lung cancer.

Connect with a clinical trial site
Recruiting
Sigvotatug Vedotin for Advanced Solid Tumors

This Phase 1 study will evaluate sigvotatug vedotin monotherapy and in
combination with pembrolizumab for patients with advanced solid tumors.

View clinical trial listing


TO CONNECT WITH PFIZER ABOUT THE BE6A PROGRAM CLICK HERE.

Is this page helpful?


References

1. Lyon, RP, Jonas M, Frantz C et al. SGN-B6A: A new vedotin antibody-drug
conjugate directed to integrin beta-6 for multiple carcinoma indications. Mol
Cancer Ther. 2023;MCT02200817. doi:10.1158/1535-7163
2. Hollebecque A, Lopez J, Piha-Paul S, et al. A first-in-human of an integrin
beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with
advanced solid tumors: interim results of a phase 1 study (SGN-B6A-001). J
Immunother Cancer. 2022;10(Suppl 2):A763
3. Hollebecque A, Lopez J, Piha-Paul, SA, et al. A first-in-human trial of an
integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients
with advanced solid tumors: Interim results of a Phase 1 study (SGNB6A-001).
Poster presented at Society for Immunotherapy of Cancer Annual Meeting; Nov
8-12. 2022; Boston, MA.
4. Lyon R, Trang V, Gosnik JJ, et al. Abstract 1522: SGN-B6A induces immunogenic
cell death as an additional mechanism of action. J ImmunoTher Cancer. 2022;
10(suppl 2). doi:10.1136/jitc-2022-SITC2022. 1186
5. Trang VH, Mazahreh R, Gosnik JJ, et al. Abstract 1522: SGN-B6A induces
immunogenic cell death as an additional mechanism of action. Cancer Res.
2023;83(suppl 7):1522-1522. doi:10.1158/1538-7445.am2023-1522
6. Van Aarsen LA, Leone DR, Ho S, et al. Antibody-mediated blockade of integrin
alpha v beta 6 inhibits tumor progression in vivo by transforming growth
factor-beta-regulated mechanism. CancerRes.
2008;68(2):561-570.doi:10.1158/008-5472.CAN07-0245
7. Elayadi AN, Samli KN, Prudkin L, et al. A peptide selected by biopanning
identifies the integrin alphabeta6 as a prognostic biomarker for nonsmall cell
lung cancer. Cancer Res. 2007:67(12):5889-5895.
8. Elez E, Kocakova I, Hokler T, et al. Abituzumab combined with cetuximab plus
irinotecan versus cetuximab plus irinotecan alone for patients with KRAS
wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON
trial. Ann Oncol. 2015;26(1):13-140. doi:10.1093/annonc/mdu474
9. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression
and metastasis. Nat Rev Cancer. 2018:18(9):533-548.
doi:10.1038/s41568-018-0038-z
10. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ. Apha vbeta
6 integrin promotes the invasion of morphoeic basal cell carcinoma through
stromal modulation. Cancer Res.
2008:68(9):3295-3303.doi:10.1158/0008-5472.CAN-08-0174

Continue reading
 * About Pfizer
 * For investigators
 * The Breakthrough newsletter

 * Site map
 * Terms of use
 * Privacy policy
 * Contact us

Information on this website is directed toward U.S. residents only.

© 2024 Pfizer Inc. All rights reserved.

 * 
 * 
 * 


ARE YOU A HEALTHCARE PROFESSIONAL?

This information is intended for U.S. Healthcare Professionals only. Are you a
Healthcare Professional in the U.S.?

YesNo
`



Back to top
We need your consent to proceed
We use and store your consent for 13 months with 30 partners for Essential,
Analytics, Personalisation, Marketing unless you change your preferences.

We use cookies to enhance your website experience. We use necessary cookies to
ensure our website functions properly and to keep it secure. These always need
to be on. We use analytics cookies to measure website use, to learn what content
is most useful to users and to help us improve it. We use marketing cookies to
help us share content with you that you may find interesting and relevant. We
use personalisation cookies to help manage your preferences and remember your
settings. For more information see our Cookie Notice.

You can change your settings or revoke your consent at any point in the future
by clicking on the button which will appear in the bottom right of your screen.


Manage SettingsReject AllAccept All
Close  ✖